Technology ID
E-241-2001-1

Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag

Linked ID
TAB-1698
Inventors
Gary Nabel (NIAID)
Zhi-yong Yang (NIAID)
Lead Inventors
Gary Nabel (NIAID)
Co-Inventors
Zhi-yong Yang (NIAID)
Development Status
Animal (mouse) data available
Therapeutic Areas
Infectious Disease
ICs
NIAID
Commercial Applications
HIV vaccine
HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified as contributing to the decreased immunogenicity observed for HIV Gag. Replacement of these regions with corresponding SIV sequences significantly increased the resulting T-cell response to HIV Gag in mice. Utilization of these chimera in an HIV vaccine could significantly enhance the overall immunogenicity of the vaccine.

Request More Info

Licensing Contact